The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

AIMS: The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim Pharma GmbH & Co. KG), shows potential as an oral antithrombotic agent. Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Stangier, Joachim, Rathgen, Karin, Stähle, Hildegard, Gansser, Dietmar, Roth, Willy
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Science Inc 2007
Soggetti:
Pharmacokinetics & Pharmacodynamics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2000643/
https://ncbi.nlm.nih.gov/pubmed/17506785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02899.x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi